Efficacy of bufexamac (NFN) cream in skin diseases. A double-blind multicentre trial.
The effect of a new non-steroid anti-inflammatory substance (bufexamac) in a special constituent was compared with that of 0.1% triamcinolone acetonide, 1% hydrocortisone cream, and placebo during a double-blind multicentre trial. The clinical effect of these four creams was studied in 193 patients receiving treatment for the following skin disorders: atopic dermatitis, allergic contact dermatitis, and non-allergic contact dermatitis, as well as dermatitis seborrheica. After 2 and 4 weeks' treatment, when 193 and 157 patients, respectively, were re-examined, the effect of triamcinolone acetonide and hydrocortisone cream was significantly better, than that obtained with bufexamac in the cream basis employed. On the other hand, no statistically significant difference in effect between bufexamac and placebo cream was observed.
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002019:Bufexamac / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003876:Dermatitis, Atopic / Q000188:drug therapy; D003877:Dermatitis, Contact / Q000188:drug therapy; D012628:Dermatitis, Seborrheic / Q000188:drug therapy; D004341:Drug Evaluation; D006801:Humans; D006854:Hydrocortisone; D006877:Hydroxamic Acids / Q000627:therapeutic use*; D010919:Placebos; D012871:Skin Diseases / Q000188:drug therapy*; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D006877:Hydroxamic Acids; D010919:Placebos; D002019:Bufexamac; D014222:Triamcinolone Acetonide; D006854:Hydrocortisone